Bluejay Therapeutics

Bluejay Therapeutics develops liver disease treatments, led by an antibody for hepatitis B and D.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series C
Initial Investment Year
2024
Blue Jay Portco Hover Image